Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Garland, Suzanne M ^a,b,c,d   Brotherton, Julia M L ^a,e,f   Condon, John R ^g   McIntyre, Peter B ^e   Stevens, Matthew P ^a   Smith, David W ^h   Tabrizi, Sepehr N ^a,b,c,d  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^f VICTORIAN CYTOLOGY SERVICE   (Australia)

^g MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^h PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; CANCER SCREENING; COMMUNITY CARE; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INDIGENOUS PEOPLE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SMOKING; UTERINE CERVIX CANCER; VACCINATION; AGE; CLASSIFICATION; CYTOLOGY; ETHNIC GROUP; GENETICS; GEOGRAPHY; ISOLATION AND PURIFICATION; METHODOLOGY; MOLECULAR DIAGNOSIS; MOLECULAR TYPING; PAPILLOMA VIRUS; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AUSTRALIA; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; ETHNIC GROUPS; FEMALE; GENOTYPE; GEOGRAPHY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TYPING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; VAGINAL SMEARS; YOUNG ADULT;

EID: 80052652114     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-104     Document Type: Article

References (43)

1. Australian Institute of Health and Welfare 2010 Cervical screening in Australia 2007-2008: data report. Cancer series no 54 Cat no CAN 50 2010, Canberra: AIHW, Australian Institute of Health and Welfare 2010.
2. De Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Valejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Ijazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GAH, Lombardi LE, Banjo A, , et al. on behalf of the Retrospective International Survey and HPV Time Trends Study Group Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-56. 10.1016/S1470-2045(10)70230-8, 20952254, on behalf of the Retrospective International Survey and HPV Time Trends Study Group.
3. Stevens MP, Tabrizi SN, Quinn MA, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial or cervical cancer in Melbourne, Australia. Int J of Gynecol Cancer 2006, 16:1017-24.
4. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamram U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, . for the HPV PATRICIA Study Group Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-14. 10.1016/S0140-6736(09)61248-4, 19586656, for the HPV PATRICIA Study Group.
5. Garland SM, Hernandez AM, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-43. 10.1056/NEJMoa061760, 17494926.
6. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-27. FUTURE II Study Group.
7. Roche P, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, Fielding J, Giele C, Gilmour R, Holland R, Kampen R, , Brown M, Gilbert L, Hogg G, Murphy D, . Enhanced invasive Pneumococcal Disease Surveillance Working Group, Pneumococcal Working Party of the Communicable Diseases Network Australia Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008, 32(1):18-30. Enhanced invasive Pneumococcal Disease Surveillance Working Group, Pneumococcal Working Party of the Communicable Diseases Network Australia.
8. Newall AT, MacIntyre R, Wang H, Hull B, Macartney K. Burden of severe rotavirus disease in Australia. J Paediatr Child Health 2006, 42(9):521-7. 10.1111/j.1440-1754.2006.00915.x, 16925538.
9. Patel MS. Australia's century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med J Aust 2007, 186(3):136-141.
10. Australian Government Department of Health and Ageing Second National Sexually Transmitted Infections Strategy 2011-2013. 2010, ISBN: 978-1-74241-248-1 Online ISBN: 978-1-74241-249-8 Publications Number: 6661. Canberra, Australian Government Department of Health and Ageing., http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-national-strategies-2010-sti/$File/sti.pdf
11. Smith D, Brestovac B, Harnett G, Frost F. Predicting the impact of new HPV vaccines on carcinoma of the uterine cervix in Western Australia. Presented at the Communicable Diseases Control Conference, Canberra, 31 March - 1 April 2003
12. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43(4 Suppl). S5-25, S25.e1-41.
13. de Sanjosé S, Diaz M Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases 2007, 7(7):453-459. 10.1016/S1473-3099(07)70158-5, 17597569.
14. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1157-64. 10.1158/1055-9965.EPI-04-0812, 15894666.
15. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202(12):1789-1799. 10.1086/657321, 21067372.
16. Bowden FJ, Tabrizi S, Paterson BA, Garland SM, Fairley CK. Determination of genital human papillomavirus genotypes in women in Northern Australia using a novel, self-administered tampon technique. Int J Gynecol Cancer 1998, 8:471-475.
17. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, Wheeler CM. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001, 183:1554-1564. 10.1086/320696, 11343204.
18. Australian Bureau of Statistics National Regional Profile Cat.No.1379.0.55.001. 29-3-2005 Australian Bureau of Statistics, 21-10-0005, Australian Bureau of Statistics.
19. Pink B, Allbon P. The Health and Welfare of Australia's Aboriginal and Torres Strait Islander Peoples 2008. Australian Bureau of Statistics cat no 4704.0/Australian Institute of Health and Welfare cat no IHW21 Commonwealth of Australia: Canberra.
20. Read C, Bateson D, Ohrin C. Effect of community consultation on recruitment of Indigenous women to a human papillomavirus prevalence study. Med J Aust 2008, 189(4):233.
21. Read CM, Bateson DJ. Marrying research, clinical practice and cervical screening in Australian Aboriginal women in western New South Wales, Australia. Rural and Remote Health 2009, 9:1117. online., http://www.rrh.org.au
22. National Health and Medical Research Council Screening to prevent cervical cancer: guidelines for management of asymptomatic women with screen detected abnormalities. 2005, National Health and Medical Research Council, National Health and Medical Research Council., http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/wh39.pdf.
23. Stevens MP, Garland SM, Tabrizi SN. Human papillomavirus genotyping using a modified linear array detection protocol. J Virol Methods 2006, 135(1):124-6. 10.1016/j.jviromet.2006.02.007, 16564098.
24. Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007, 45(7):2130-7. 10.1128/JCM.02438-06, 1933009, 17494721.
25. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38:357-61. 88724, 10618116.
26. Garland SM, Tabrizi SN, Chen S, Byambaa C, Davaajav K. Prevalence of sexually transmitted infections (Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and human papillomavirus) in female attendees of a sexually transmitted diseases clinic in Ulaanbaatar, Mongolia. Infect Dis Obstet Gynecol 2001, 9(3):143-6. 10.1155/S1064744901000254, 1784652, 11516062.
27. Stevens MP, Garland SM, Tabrizi SN. Validation of an automated detection platform for use with the Roche linear array human papillomavirus genotyping test. J Clin Microbiol 2008, 46(11):3813-6. 10.1128/JCM.01169-08, 2576620, 18784316.
28. Stevens MP, Rudland E, Garland SM, Tabrizi SN. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol 2006, 44(7):2428-33. 10.1128/JCM.02608-05, 1489532, 16825360.
29. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, Zhang R, Sherman ME, Wacholder S, Walker J, Wang SS. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009, 125:2151-2158. 10.1002/ijc.24528, 2755508, 19585494.
30. Zubrick SR, Silburn SR, Lawrence DM, Mitrou FG, Dalby RB, Blair EM, Griffin J, Milroy H, De Maio JA, Cox A, Li J. The Western Australian Aboriginal Child Health Survey. Volume 2: The social and emotional wellbeing of Aboriginal children and young people. 2005, Perth: Curtin University of Technology and Telethon Institute for Child Health Research.
31. Australian Institute of Health and Welfare 2010 Australia's health 2010. Australia's health series no 12 Cat no AUS 122 Canberra: AIHW, Australian Institute of Health and Welfare 2010.
32. Reath J, Carey M. Breast and cervical cancer in indigenous women. Overcoming barriers to early detection. Aust Fam Physician 2008, 37:178-182.
33. Franceschi S, Plummer M, Clifford G, de Sanjose S, Bosch X, Herrero R, Muñoz N, Vaccarella S, , . International Agency for Research on Cancer Multicentric Cervical Cancer Study Groups, International Agency for Research on Cancer Human Papillomavirus Prevalence Surveys Study Group Differences in the risk of cervical cancer and human papillomavirus infection by education level. Br J Cancer 2009, 101(5):865-70. 10.1038/sj.bjc.6605224, 2736843, 19654578, International Agency for Research on Cancer Multicentric Cervical Cancer Study Groups, International Agency for Research on Cancer Human Papillomavirus Prevalence Surveys Study Group.
34. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, 24S3:S3/52-S3/61.
35. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type - and age-specific distribution of HPV in women before introduction of an HPV vaccination program in Denmark. Int J Cancer 2008, 123:1864-70. 10.1002/ijc.23712, 18661520.
36. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Path 2004, 57:68-72. 10.1136/jcp.57.1.68, 1770158, 14693839.
37. Hibbitts S, Jones J, Powell N, Dallimore N, McRea J, Beer H, Tristram A, Fielder H, Fiander AN. Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: A cross-sectional study. Brit J Cancer 2008, 99:1929-1933. 10.1038/sj.bjc.6604748, 2600697, 19034285.
38. Australian Bureau of Statistics Tobacco Smoking in Australia: A Snapshot, 2004-05. 4831.0.55.001. Australian Bureau of Statistics., http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/4831.0.55.001Main%20Features12004-05?opendocument&tabname=Summary&prodno=4831.0.55.001&issue=2004-05&num=&view=
39. Richters J, Grulich AE, Visser RO, Smith AMA, Rissel CE. Sex in Australia: Contraceptive practices among a representative sample of women. Aust NZ J Public Health 2003, 27(2):210-216.
40. Dunne EF, Unger ER, Maya Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819. 10.1001/jama.297.8.813, 17327523.
41. Australian Bureau of Statistics The Australian Health Survey - FAQs. Australian Bureau of Statistics., http://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Health+Survey+-+Frequently+Asked+Questions
42. Newall AT, Brotherton JML, Quinn HE, Backhouse JL, McIntyre PB, Gilbert GL, Esser MT, Erick J, Bryan J, Formica N, MacIntyre R. Population seroprevalence to human papillomavirus types 16/18/6/11 in men, women and children in Australia. Clin Infect Dis 2008, 46:1647-55. 10.1086/587895, 18444790.
43. World Health Organisation Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009, 84(15):118-131. World Health Organisation.